Bone marrow transplantation activity in Europe 1992: report from the European Group for Bone Marrow Transplantation (EBMT).
Bone marrow transplantation activity in Europe 1992: report from the European Group for Bone Marrow Transplantation (EBMT).
复制标题
1992 年欧洲的骨髓移植活动：欧洲骨髓移植组织 (EBMT) 的报告。
DOI：
--
复制
发表时间：
1994
影响因子：
4.8
通讯作者：
J. Hermans
中科院分区：
文献类型：
--
作者：
A. Gratwohl;J. Hermans
1992年，欧洲26个国家的203个团队共进行了6065例骨髓移植。2666例(44%)移植供者为异基因供者，2171例为人类白细胞抗原相合的同胞供者，170例为异基因家庭供者，29例为双胞胎供者，296例为无血缘关系的自愿供者。其中自体骨髓移植2494例，自体外周血干细胞移植644例，自体骨髓与外周血干细胞联合移植261例。移植的适应症是2963例患者(49%；1987例异体，976例自体)，1890例淋巴增生性疾病(31%；201例异体，1689例自体)，739例实体瘤(12%，10例异体，739例自体)，194例再生障碍性贫血(3%；193例，1例自体)，128例地中海贫血(2%，异体)，115例先天错误(2%；异体)，36例其他疾病(32例，4例)。与两年前的EBMT调查相比，参与机构的数量和从所有来源进行的移植数量都有所增加。如果将1990年和1992年报告的142个研究小组单独进行比较，则无关的异基因骨髓移植和自体骨髓移植的发生率都有所增加。骨髓瘤和淋巴瘤的自体移植有所增加。这些数据证实了将骨髓移植作为一种治疗方式的持续趋势。
In the year 1992, 203 teams in 26 countries in Europe performed a total of 6065 bone marrow transplantations (BMT). Transplant source in 2666 cases (44%) was an allogeneic donor, in 2171 cases an HLA-identical sibling donor, in 170 a non-identical family donor, in 29 a twin donor and in 296 cases an unrelated volunteer donor. There were 3399 autologous transplants (56%): 2494 autologous BMT, 644 autologous peripheral blood stem cell transplants and 261 combined autologous BM and peripheral blood stem cell transplants. Indications for transplant were leukemias in 2963 patients (49%; 1987 allogeneic, 976 autologous), lymphoproliferative disorders in 1890 patients (31%; 201 allogeneic, 1689 autologous), solid tumors in 739 patients (12%; 10 allogeneic, 739 autologous), aplastic anemia in 194 patients (3%; 193 allogeneic, 1 autologous), thalassemia in 128 patients (2%; allogeneic), inborn errors in 115 patients (2%; allogeneic) and miscellaneous disorders in 36 patients (32 allogeneic, 4 autologous). Compared with an EBMT survey 2 years ago, there was an increase in the number of participating institutions and in the number of transplants performed from all sources. If the 142 teams reporting in 1990 and 1992 are compared alone, there is an increase in unrelated allogeneic BMT and in autologous BMT. There was an increase in autologous transplants for myeloma and lymphoma. These data confirm a continuing trend to apply BMT as a therapeutic modality.